Skip to main content
NCBI home page
Case Reports in Dermatology logoLink to Case Reports in Dermatology
. 2025 Jun 23;17(1):204–223. doi: 10.1159/000546382

Cutaneous Rosai-Dorfman Disease: A Report of 2 Cases and a Review of Recent Literature (2018–2023)

Fatemeh Mohaghegh a, Mina Saber a, Parvin Rajabi b, Haniyeh Sohrabi c,✉
PMCID: PMC12185066  PMID: 40551960

Abstract

Introduction

Rosai-Dorfman disease (RDD) is a rare, benign histiocytic disorder that can present as isolated cutaneous RDD (CRDD), often mimicking other dermatologic conditions and complicating diagnosis.

Case Presentation

We report two cases of CRDD: one with palms and soles involvement, and another as an exophytic facial mass, initially misdiagnosed and unsuccessfully treated. Dermoscopy revealed distinctive features, including yellow ovoid structures, linear vessels, and cotton-like white globules. Histopathological and immunohistochemical analyses confirmed CRDD with histiocytic infiltration and emperipolesis, key histological markers of CRDD.

Conclusion

A review of 53 cases (2018–2023) highlights CRDD’s clinical variability, common anatomical sites, and diverse treatment responses, emphasizing the need for individualized management and early recognition for optimal treatment. These findings contribute to a broader understanding of CRDD and support a multidisciplinary approach to optimizing patient care.

Keywords: Rosai-Dorfman disease, Sinus histiocytosis, Skin, Emperipolesis, Case report

Introduction

Rosai-Dorfman disease (RDD) or sinus histiocytosis with massive lymphadenopathy is a rare, acquired, idiopathic, benign systemic proliferative disorder of histiocytes [1]. The typical Clinical features of the disease include bilateral painless massive lymphadenopathy, as well as general symptoms such as fever, night sweats, weight loss, and fatigue [2]. Skin lesions are the most common form of extra nodal involvement approximately 43% [3]. However, a cutaneous variant of RDD (CRDD) is very rare and occurs without lymphadenopathy or internal organ involvement. CRDD, also known as cutaneous sinus histiocytosis, accounts for approximately 3% of RDD cases [4]. The histopathological features of CRDD closely resemble those of systemic RDD, particularly in lymph nodes. However, some studies indicate that CRDD tends to exhibit more pronounced fibrosis and sclerosis, along with a reduced number of histiocytes and less prominent emperipolesis [5, 6]. RDD typically presents with cervical lymphadenopathy, most commonly in children or young adults, with a median age of onset around 20 years. It is more frequently observed in males, particularly those of African descent [7]. In contrast, CRDD is more commonly seen in middle-aged females, predominantly of Asian or Caucasian backgrounds [8].

CRDD often presents as yellowish or violaceous nodules or plaques and an erythematous base, primarily affecting the head and neck region [9]. Its diagnosis can be challenging due to similarities with conditions such as xanthomas, Kaposi sarcoma, cutaneous lymphoma, tuberculosis, and Langerhans cell histiocytosis [10, 11]. There is no standardized treatment for RDD, so management is tailored to each case. Systemic RDD may not require intervention in asymptomatic cases, but symptomatic or severe forms are treated with corticosteroids, thalidomide, methotrexate, imatinib, rituximab, chemotherapy, or radiotherapy [12].

CRDD is usually managed with topical or intralesional corticosteroids, imiquimod, cryotherapy, or surgical excision for symptom relief. Systemic therapies are rarely required, but may be considered for severe or persistent cases [8, 13]. The diagnosis and management of CRDD are particularly challenging due to its variable presentation, numerous differential diagnoses, and the absence of standardized treatments. Sharing case experiences is crucial to improving understanding and guiding care. This manuscript highlights two cases of CRDD, offering valuable insights into this rare condition.

Case Reports

Case 1

A 30-year-old Caucasian male presented with a 1-year history of generalized papulonodular cutaneous lesions. The first lesion appeared as a painful nodule on the plantar surface, followed by the gradual development of additional papulonodular lesions on the face, hands, and axilla.

The initial lesions were painful purple papules, some of which progressed into nodules, while others spontaneously resolved, leaving post-inflammatory hyperpigmentation. The initial lesions were painful purple papules. Some progressed into nodules, while others spontaneously resolved, leaving post-inflammatory hyperpigmentation.

The patient denied symptoms like pruritus, malaise, or weight loss. Laboratory investigations showed no abnormalities or indications of underlying systemic disease. Physical examination showed no fever, lymphadenopathy, or organomegaly. Clinical examination revealed grouped purple to skin-colored papules and plaques with a hyperpigmented patch due to the healing of previous lesions (Fig. 1).

Fig. 1.

Fig. 1.

Open in a new tab

Clinical appearance of widespread papulonodular cutaneous lesions.

Dermoscopy at 20-fold magnification (FotoFinder Handyscope®) of trunk and limb lesions revealed a pink-brown background, large yellow ovoid structures, and linear vessels. Dermoscopy of the plantar lesion showed cotton-like white globular structures over a pink background accompanied by hemorrhagic dots and peripheral scaling (Fig. 2).

Fig. 2.

Fig. 2.

Open in a new tab

a Large yellow ovoid structures accompanied by linear vessels on a brown-pink background. b Cotton-like white globular structures over a pink background accompanied by hemorrhagic dots and peripheral scaling.

Histopathologic evaluation revealed a dense dermal infiltrate of histiocytes and lymphocytes. The histiocytes had vesicular nuclei, abundant eosinophilic cytoplasm, and areas of emperipolesis (Fig. 3). Once pathology confirmed the diagnosis of RDD, computed tomography of the chest and neck, along with abdominopelvic ultrasonography, revealed no evidence of organomegaly or lymphadenopathy.

Fig. 3.

Fig. 3.

Open in a new tab

Areas of emperipolesis and a thick dermal infiltrate of large histiocytes mixed with lymphocytes were observed in the histopathologic assessment. H&E staining. a ×10, b ×40, c, d ×100.

Given the absence of systemic involvement, a diagnosis of CRDD was made. During follow-up, intralesional triamcinolone acetonide (0.5 cc of 10 mg/mL) was administered, leading to mild improvement.

Case 2

A 35-year-old Caucasian man presented with a 9-month history of two facial lesions. The initial lesion appeared as an asymptomatic, erythematous, scaly plaque on the right cheek, which gradually enlarged into an exophytic papillomatous mass. A similar but smaller lesion later developed on the opposite cheek. The patient was otherwise healthy, with no significant past medical history or family history of malignancies. As a welder and had no significant exposure to irritants other than grease. He had not traveled in the past year and denied contact with pets. Physical examination revealed a red, exophytic papillomatous mass approximately 7 cm in diameter, on the right cheek and an erythematous plaque approximately 2 cm in diameter on the left cheek (Fig. 4).

Fig. 4.

Fig. 4.

Open in a new tab

A 2 cm wide erythematous plaque is placed on the left cheek (b), and a red exophytic and Papillomatous mass with a diameter of 7 cm is present on the right cheek (a). Right cheek after surgery (c) and a recently developed lesion on the forearm (d).

Dermoscopy showed large yellow ovoid structures, well-defined linear vessels, follicular plugging, perifollicular scaling, and interfollicular linear white opaque structures (Fig. 5). No systemic symptoms, such as fever, malaise, or weight loss, or lymphadenopathy were noted. Detailed laboratory analyses, including a complete blood count and biochemical tests, were within normal ranges. In culture from lesion secretions, coagulase-negative staphylococcus was reported. Fungal culture and smear were reported as negative. Leishmanin and PPD skin tests were also negative.

Fig. 5.

Fig. 5.

Open in a new tab

Large yellow ovoid structures accompanied by sharp focused linear vessels. Obvious follicular plugging, perifollicular scaling, and white linear opaque interfollicular structures (a, b).

He had previously been treated with antibiotics and antifungal agents by another clinician, but no significant improvement was observed. A biopsy specimen was obtained from the lesion, and a histopathological study followed by immunohistochemical (IHC) staining for the patient. Histopathologic analysis revealed hyperkeratosis and acanthosis of the epidermis. In the dermis, there was diffuse infiltration of histiocytes and lymphoplasma cells. Most histiocytes had abundant clear cytoplasm with engulfment of lymphocytes (emperipolesis) in their cytoplasm (Fig. 6). The histiocytes were positive for S-100 and CD68, but negative for CD1a (Fig. 7). Abdominal ultrasound and chest X-ray were unremarkable, confirming the absence of systemic involvement. A surgical approach was selected due to the localized nature of the lesions.

Fig. 6.

Fig. 6.

Open in a new tab

Histiocytes and lymphoplasma cells were observed in the dermis with diffuse infiltration. The majority of histiocytes had a large amount of clear cytoplasm that was engulfed by lymphocytes (emperipolesis). H&E staining, a ×10, b ×100.

Fig. 7.

Fig. 7.

Open in a new tab

The histiocytes were negative for CD1a (b) but significantly positive for S-100 (a) and CD68 (c).

Four months of follow-up showed no recurrence of the large lesion on the right cheek. A new lesion developed on the forearm, which was excised and confirmed as CRDD on pathology.

Discussion

Classic cutaneous RDD presents as slow-growing, multifocal, grouped satellite lesions, presenting as firm, red to red-brown or xanthomatous macules, papules, nodules, or plaques [14, 15]. Soft tissues, especially the skin, subcutaneous tissue, orbit, and eyelids, are commonly affected [3].

Regarding clinical presentation, our CRDD cases involved multifocal, painful lesions on the face, plantar region, hands, and soles. In contrast, Banbury et al. [16] reported four patients of African descent with localized, asymptomatic or mildly tender papules and nodules, primarily on the face, abdomen, knees, and thighs. Additionally, these patients experienced prolonged disease durations, with some lesions persisting for over a decade. This highlights the variability in CRDD presentations influenced by racial and ethnic factors.

Recent studies have described dermoscopic features of cutaneous RDD, including red-orange background, yellowish ovoid structures, linear vessels, white opaque structures, cotton-like white globular structures, and white crystalline structures [17–20]. The large yellow ovoid structures in our cases likely represent compact multinodular infiltration of lipid-rich lymphohistiocytes in the dermis. The prominent follicular plugging in our second case may be attributed to a dilated follicular infundibulum containing keratotic debris [17].

Bennouna et al. [21] reported a case involving a 25-year-old woman with a gradually enlarging facial lesion, characterized by dermoscopic findings including orange-yellowish areas, radial hairpin vessels, and follicular keratotic plugs set against a red-orange background. The presence of hairpin vessels, more commonly linked to keratinizing tumors, in this case of CRDD highlights the diverse and atypical dermoscopic patterns that can be observed in this rare disorder [21].

Cotton-like structures in palmoplantar RDD have been described by Rodríguez-Blanco et al. [20]. Our observation of these structures in the first case suggests they could be a distinctive dermoscopic feature of palmoplantar RDD.

Histopathologic examination is essential for diagnosing RDD, with emperipolesis as a hallmark. In the cutaneous form of RDD, emperipolesis may be less prominent, which increases the risk of misdiagnosis compared to the nodal form [22]. Typical histologic findings include histiocytic infiltrates, eosinophilic cytoplasm, vesicular nuclei, the presence of plasma cells, and lymphocytes [18].

Immunohistochemistry reveals S-100 and CD68 positivity with CD1a negativity, distinguishing RDD from other histiocytic disorders such as Langerhans cell histiocytosis, histiocytic sarcoma, Erdheim-Chester disease, tuberculosis, and leprosy [23]. Both cases in our study exhibited these characteristic histopathologic and IHC features.

Systemic and cutaneous RDD has an uncertain etiology. However, laboratory findings frequently indicate an immune dysfunction triggered by an antigen or infectious organism, an autoimmune process, or a neoplastic condition, as suggested by case reports and small studies [3, 24, 25]. Coagulase-negative staphylococcus was found in Case 2, but further research is required to determine the specific cause.

Other histiocytic lesions, such as Langerhans cell histiocytosis, histiocytic sarcoma, Hodgkin lymphoma, and Erdheim-Chester disease, as well as inflammatory/reactive disorders, including infectious granulomatous diseases, should be considered in the differential diagnosis [26]. RDD may also coexist with lymphoproliferative disorders, including non-Hodgkin or Hodgkin lymphoma and mycosis fungoides [6, 27].

Treatment for CRDD requires an individualized, multidisciplinary approach. For patients with minimal or slowly progressing lesions, observation may be appropriate [28]. Localized lesions may respond to topical or intralesional corticosteroids, such as triamcinolone acetonide, which led to mild improvement in our first case. Cryotherapy is an alternative for smaller lesions, while surgical excision is preferred for larger or cosmetically significant lesions, as demonstrated in our second case. Systemic corticosteroids, methotrexate, and rituximab are alternatives, requiring careful monitoring for adverse effects [13].

In more complex cases, recent studies have proposed alternative treatment options. Al-Ghawas et al. [29] explored the use of lenalidomide and dexamethasone for a patient with CRDD who did not respond to intralesional steroids, prednisone, or rituximab, and where surgery was not viable due to potential facial defects. This combination therapy resulted in notable improvement and appears to be a potential option for refractory CRDD [29].

Localized radiotherapy may be a suitable option for managing CRDD, especially when other treatments have not been effective or have only provided partial relief. It has been associated with moderate lesion improvement and minimal side effects, such as radiodermatitis. Thus, radiotherapy could be considered a viable option, particularly for cases confined to the skin [30].

To improve understanding of CRDD’s uncommon presentation, A literature review was conducted, focusing on studies published between January 2018 and December 2023. This period was chosen to build on a previous evaluation completed in 2018 [2]. The search was conducted using Google Scholar and PubMed with the query “Cutaneous Rosai-Dorfman Diseas.” Inclusion criteria were limited to original publications, including case reports, case series, and letters to the editor confirming CRDD through histopathologic analysis.

Initially, 54 articles were identified. After reviewing abstracts and full texts, eight were excluded for not focusing on CRDD or lacking original case data. Ultimately, 46 articles met the inclusion criteria and were analyzed. The selected studies are summarized in Table 1.

Table 1.

Reported cases of CRRD (2018–2023): patient characteristics and clinical findings

Author Age/gender Lesions, n Site of lesions Immunohistochemistry Histology Comorbidities Treatment Outcome
Current study 30/Male Multiple Face S-100+ Emperipolesis None Steroids Improvement
Head and neck CD68+
Extremities CD1a−
Current study 35/Male Multiple Face S-100+ Emperipolesis None Excision Improvement
Extremities CD68+
CD1a−
Tirado-Sánchez [31] (2023) 56/Female Multiple Extremities S-100+ Emperipolesis None Excision Improvement
Steroids
CD68+ MTX
Trunk Radiation
CD1a− Sirolimus
Thalidomide
St Claire et al. [32] (2023) 65/Male Multiple Trunk S-100+ Emperipolesis None Not mentioned No data
CD1a−
Sasaoka et al. [33] (2023) 64/Male Multiple Extremities S-100+ Emperipolesis None Sirolimus Improvement
Trunk CD68+ Steroids
CD1a−
Hur et al. [34] (2023) 47/Female Multiple Face S-100+ Emperipolesis Not mentioned Excision Improvement
CD68+ Steroids
CD1a−
Fay et al. [35] (2023) 60/Male Multiple Face S-100+ Emperipolesis None MTX Trametinib Improvement
CD68+ Steroids
CD1a−
Banbury et al. [16] (2023) 59/Female Multiple Face, trunk S-100+ Emperipolesis None Steroids, MTX, lenalidomide, rituximab Refractory, lost to follow-up
Extremities CD68+
CD1a−
Banbury et al. [16] (2023) 70/Female Multiple Face S-100+ Emperipolesis None Steroids, tacrolimus, MTX Improvement
CD68+ Hydroxychloroquine
CD1a−
Banbury et al. [16] (2023) 75/Female Multiple Extremities S-100+ Emperipolesis Breast cancer, marginal zone lymphoma Declined treatment Declined treatment
CD1a−
Banbury et al. [16] (2023) 50/Female Single Extremities S-100+ Emperipolesis None Antibiotic, steroids excision Improvement
CD68+
CD1a−
Balestri et al. [36] (2023) 47/Female Multiple Extremities S-100+ Emperipolesis None Excision Improvement
Face CD68+ Antibiotics
CD1a−
Roccuzzo et al. [37] (2023) 72/Male Multiple Extremities S-100+ Emperipolesis Primary cutaneous Rituximab Improvement
CD68+ B-cell lymphoma
CD1a−
Gitin et al. [38] (2022) 39/Female Multiple Extremities S-100+ Emperipolesis HIV infection Not mentioned No data
CD68+
CD1a−
Konstantinou and Tournier [39] (2022) 66/Male Multiple Trunk S-100+ Emperipolesis RET and MAP2K1 mutations Steroids Improvement
Face CD68+ MTX
Head and neck CD1a−
Choi et al. [30] (2022) 43/Female Multiple Trunk S-100+ Emperipolesis Not mentioned Steroids Improvement
Radiation
Battista et al. [40] (2022) 33/Male Single Face S-100+ Emperipolesis None Excision Improvement
CD68+
CD1a−
Mekheal et al. [41] (2022) 24/Female Single Trunk S-100+ Emperipolesis None Steroids Improvement
CD68+
CD1a−
Grimaldiet al. [42] (2022) 62/Male Multiple Extremities S-100+ Emperipolesis CDD following coronavirus-19 vaccination Thalidomide Improvement
Trunk
Narayanan et al. [43] (2022) 52/Female Single Face S-100+ Emperipolesis Not mentioned Antibiotics Improvement
Maghfour et al. [44] (2021) 30/Male Multiple Face S-100+ Emperipolesis None Steroids Improvement
CD68+
CD1a−
Gawdzik et al. [45] (2021) 69/Female Multiple Extremities S-100+ Emperipolesis Cytomegalovirus, Epstein-Barr virus, Borrelia burgdorferi infection Excision Improvement
CD68+ Steroids
CD1a− MTX
Shen et al. [19] (2021) 57/Male Multiple Trunk S-100+ Emperipolesis Not mentioned Radiation No data
CD68+
Yuan et al. [46] (2021) 45/Male Multiple Trunk no data Emperipolesis None Steroids Improvement
Zhang et al. [47] (2021) 47/Female Multiple Trunk S-100+ Emperipolesis None Steroids Improvement
Face CD68+
CD1a−
Jain et al. [48] (2021) 36/Female Single Extremities S-100+ Emperipolesis None No data Improvement
CD68+
CD1a−
Sampaio et al. [49] (2021) 27/Female Multiple Trunk S-100+ Emperipolesis Not mentioned Steroids Improvement
Face CD68+ Antibiotics
CD1a−
Kipfer et al. [50] (2021) 59/Female Multiple Trunk S-100+ Emperipolesis Follicular B-cell lymphoma Steroids Improvement
Face Antibiotics
CD1a− Myelodysplastic syndrome (MDS) Antihistamine
Head and neck Tacrolimus
Montazer et al. [51] (2021) 45/Female Single Trunk S-100+ Emperipolesis None Not mentioned No data
CD68+
CD1a−
Fayne et al. [52] (2020) 38/Female Single Extremities S-100+ Emperipolesis None Steroids No significant improvement
CD68+ Imiquimod
CD1a−
Fayne et al. [52] (2020) 63/Female Multiple Extremities S-100+ Emperipolesis None Steroids No significant improvement
CD68+
CD1a−
Fayne et al. [52] (2020) 45/Female Single Trunk S-100+ Emperipolesis Genital herpes Excision No data
CD68+ Steroids
CD1a− Radiation, vinblastine
Fayne et al. [52] (2020) 55/Female Multiple Extremities S-100+ Emperipolesis syphilis Steroids No significant improvement
Trunk CD68+ Hepatitis C
CD1a−
Bielach-Bazyluk et al. [53] (2020) 52/Female Multiple Extremities S-100+ Emperipolesis Chlamydia trachomatis Antibiotics No data
CD68+ Syphilis MTX
CD1a− Cervical cancer Radiation
Naqvi and Cassarino [54] (2020) 47/Male Single Extremities S-100− Emperipolesis CRDD arose in a background of a black tattoo Not mentioned No data
CD68+
El-Kamel et al. [10] (2020) 46/Male Multiple Extremities S-100+ Emperipolesis None Not mentioned No data
Trunk CD68+
Face CD1a−
Wan et al. [55] (2020) 40/Female Single Face S-100+ Emperipolesis Not mentioned Excision Improvement
CD68+ ALA-PDT
CD1a−
Mizuta et al. [56] (2020) 51/Male Single Head and neck S-100+ Emperipolesis None No treatment Improvement
CD68+
CD1a−
Ickx et al. [57] (2019) 43/Male Single Trunk No data No data None Excision No data
Ickx et al. [57] (2019) 29/Male Single Trunk No data No data None Excision No data
Karami et al. [58] (2019) 30/Male Multiple Trunk S-100+ Emperipolesis Parotid Involvement Excision Improvement
Face CD68+ Steroids
CD1a−
Gaul and Chang [9] (2019) 31/Female Multiple Extremities S-100+ Emperipolesis None Steroids Improvement
CD1a− Antibiotics
Sykes et al. [59] (2019) 76/Male Single Trunk S-100+ Emperipolesis Non-melanoma skin cancer Excision Improvement
CD68+
CD1a−
Park et al. [60] (2019) 70/Female Single Face S-100+ Emperipolesis None Steroids Improvement
CD68+ MTX
CD1a− Pulsed dye laser (PDL)
Gan et al. [61] (2019) 47/Male Multiple Trunk S-100+ Emperipolesis None Steroids Improvement
Head and neck CD68+ Thalidomide
CD1a−
Karadag et al. [62] (2019) 51/Female Multiple Extremities S-100+ Emperipolesis None Imiquimod Improvement
CD1a−
Kimet al. [63] (2019) 57/Male Multiple Extremities S-100+ Emperipolesis Rheumatoid arthritis Excision Improvement
Trunk Antibiotics
Zhang and Chen [11] (2019) 48/Male Multiple Extremities S-100+ Emperipolesis Not mentioned Not mentioned No data
Trunk CD68+
Face CD1a−
Al-Ghawas et al. [29] (2019) 30/Male Single Face S-100+ Emperipolesis None Steroids Improvement
Lenalidomide
Rituximab
Song et al. [64] (2019) 30/Female Multiple Extremities S-100+ Emperipolesis None Steroids Improvement
CD68+
Trunk CD1a−
Barona García et al. [65] (2018) 57/Female Single Head and neck S-100+ Emperipolesis None Excision Improvement
CD68+
CD1a−
Shelley and Kanigsberg [27] (2018) 63/Male Multiple Trunk S-100+ Emperipolesis Mycosis fungoides basal cell carcinomas squamous cell carcinoma Not mentioned No data
CD68+
Subash et al. [66] (2018) 48/Female Single Extremities S-100+ Emperipolesis None MTX Improvement
Gupta et al. [67] (2018) 13/Female Multiple Trunk S-100+ Emperipolesis None Not mentioned No data
Head and neck CD68+
CD1a−
Yoshimoto et al. [68] (2018) 75/Female Single Trunk S-100+ Emperipolesis Not mentioned Excision No data
CD68+
CD1a−
Open in a new tab

MTX, methotrexate.

The rarity of CRDD and limited case reports challenged the establishment of robust evidence-based conclusions. However, this review provides a valuable synthesis of recent findings and highlights the current understanding of this rare condition.

Our analysis of 53 cases from 46 articles reinforces the diverse clinical spectrum of CRDD. The reviewed cases showed a mean patient age of 49 years (range: 13–76), with a predominance of females (58%). Most cases (64%) involved multiple lesions, primarily located on the trunk (52%), and extremities (43%). Histopathologic examination consistently revealed large histiocytes with emperipolesis, and immunohistochemistry confirmed the S100+CD68+CD1a pattern in 69% of cases. CRDD was frequently associated with lymphoma, malignancies, and infections, such as HIV, cytomegalovirus, and Borrelia burgdorferi. Treatment varied, with corticosteroids (49%) and excision (28%), being the most common options. Among the 39 patients with follow-up data, 64% achieved full or partial remission, suggesting a generally favorable prognosis. These findings align with recent literature and emphasize the heterogeneity of CRDD, highlighting the importance of a multidisciplinary approach to treatment.

Conclusion

CRDD is a rare condition that poses diagnostic challenges, particularly when systemic involvement is absent, providing insights into uncommon presentations such as painful, multifocal lesions on the palms and soles. Unique dermoscopic features, including cotton-like white globular structures in palmoplantar lesions and follicular plugging in facial lesions, provide new diagnostic clues. In conjunction with hallmark histopathologic features, such as emperipolesis, and characteristic immunohistochemical staining patterns, these observations enhance the understanding of CRDD.

By highlighting these novel aspects, we aim to improve awareness of CRDD’s diverse features and stress the importance of a comprehensive diagnostic approach. Early detection and tailored treatment, as illustrated in our cases, are key to improving clinical outcomes and guiding best practices for managing this rare disorder.

The CARE Checklist has been completed by the authors for this case report, attached as online supplementary material (for all online suppl. material, see https://doi.org/10.1159/000546382).

Acknowledgments

We wish to thank in particular the patients for their collaboration.

Statement of Ethics

This case report was approved by the Ethics Committee of Isfahan University of Medical Sciences on December 2023. Written informed consent was obtained from the patients for publication of this case report and any accompanying images.

Conflict of Interest Statement

The authors declare that they have no competing interests and no financial intentions related to this manuscript.

Funding Sources

No funding was involved in the creation of this text.

Author Contributions

Dr. Fatemeh Mohaghegh was responsible for collecting the initial clinical data for the two cases, performing biopsies and related examinations, and establishing the final diagnoses. Dr. Mina Saber conducted the dermoscopic evaluations, contributed dermoscopy-related data to the manuscript, and provided consultation to enhance the accuracy of the content. Dr. Parvin Rajabi was responsible for the pathology-based diagnosis. Dr. Haniyeh Sohrabi gathered additional supporting information, compiled the data into tables, and prepared the final version of the manuscript.

Funding Statement

No funding was involved in the creation of this text.

Data Availability Statement

All data generated or analysed during this study are included in this article and its supplementary material files. Further inquiries can be directed to the corresponding author.

Supplementary Material.

References

  • 1. Ohnishi A, Yoshida Y, Yamamoto O. Cutaneous rosai-dorfman disease. J Dermatol. 2008;35(9):604–5. [DOI] [PubMed] [Google Scholar]
  • 2. Ahmed A, Crowson N, Magro CM. A comprehensive assessment of cutaneous Rosai-Dorfman disease. Ann Diagn Pathol. 2019;40:166–73. [DOI] [PubMed] [Google Scholar]
  • 3. Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol. 1990;7(1):19–73. [PubMed] [Google Scholar]
  • 4. Landim FM, Rios HO, Costa CO, Feitosa RG, Rocha Filho FD, Costa AA. Cutaneous rosai-dorfman disease. An Bras Dermatol. 2009;84(3):275–8. [DOI] [PubMed] [Google Scholar]
  • 5. Chuah KL, Tan PH, Hwang SG, Ong BH. Cutaneous Rosai-Dorfman disease--a pathologic review of 2 cases. Singapore Med J. 2000;41(3):122–5. [PubMed] [Google Scholar]
  • 6. Bruce-Brand C, Schneider JW, Schubert P. Rosai-Dorfman disease: an overview. J Clin Pathol. 2020;73(11):697–705. [DOI] [PubMed] [Google Scholar]
  • 7. Pitamber HV, Grayson W. Five cases of cutaneous Rosai-Dorfman disease. Clin Exp Dermatol. 2003;28(1):17–21. [DOI] [PubMed] [Google Scholar]
  • 8. Gameiro A, Gouveia M, Cardoso JC, Tellechea O. Histological variability and the importance of clinicopathological correlation in cutaneous Rosai-Dorfman disease. An Bras Dermatol. 2016;91(5):634–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Gaul M, Chang T. Cutaneous rosai-dorfman disease. Cutis. 2019;103(3):171–3. [PubMed] [Google Scholar]
  • 10. El-Kamel MF, Selim MK, Gawad MMA. A new presentation of isolated cutaneous Rosai-Dorfman disease: eruptive xanthoma-like lesions. Indian J Dermatol Venereol Leprol. 2020;86(2):158–61. [DOI] [PubMed] [Google Scholar]
  • 11. Zhang Y, Chen H. Image Gallery: generalized cutaneous Rosai-Dorfman disease presenting as acneiform lesions. Br J Dermatol. 2019;180(2):e36. [DOI] [PubMed] [Google Scholar]
  • 12. Abla O, Jacobsen E, Picarsic J, Krenova Z, Jaffe R, Emile JF, et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood. 2018;131(26):2877–90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Fumerton R, Ball N, Zhou Y. Refractory cutaneous Rosai-Dorfman disease responsive to cryotherapy. Cutis. 2011;87(6):296–9. [PubMed] [Google Scholar]
  • 14. Bens G, Kerdraon R, De Kyvon JJ, Estève E. [Indolent firm reddish papules. Cutaneous Rosai-Dorfman disease]. Hautarzt. 2011;62(5):384–7. [DOI] [PubMed] [Google Scholar]
  • 15. Chappell JA, Burkemper NM, Frater JL, Hurley MY. Cutaneous rosai-dorfman disease and morphea: coincidence or association? Am J Dermatopathol. 2009;31(5):487–9. [DOI] [PubMed] [Google Scholar]
  • 16. Banbury S, Chu B, Hedberg ML, Ogunleye TA, Kim E, Rosenbach M. Four cases of cutaneous Rosai-Dorfman in Black patients: a review of a single institution’s experience with this rare disease. JAAD Case Rep. 2023;42:117–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Hu C, Cao Y, Yang X, Cao Z, Xu M, Shi L, et al. Dermoscopic follow-up of cutaneous rosai-dorfman: spontaneous regression. Photodiagnosis Photodyn Ther. 2021;34:102263. [DOI] [PubMed] [Google Scholar]
  • 18. Farooq U, Chacon AH, Vincek V, Elgart GW. Purely cutaneous rosai-dorfman disease with immunohistochemistry. Indian J Dermatol. 2013;58(6):447–50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Shen X, Wang WJ, Wang ZY, Cui Y. Dermoscopic and reflectance confocal microscopic findings of cutaneous Rosai-Dorfman disease. Chin Med J. 2020;134(1):112–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Rodríguez-Blanco I, Suárez-Peñaranda JM, Toribio J. Atypical presentation and dermoscopic evaluation of cutaneous Rosai-Dorfman Disease. Acta Derm Venereol. 2009;89(4):430–1. [DOI] [PubMed] [Google Scholar]
  • 21. Bennouna N, Baline K, Hali F, Elkebir A, Marnissi F, Chiheb S. Hairpin vessels in purely cutaneous Rosai-Dorfman disease of the face: a case report. Int J Dermatol Sci. 2023;5(1):01–3. [Google Scholar]
  • 22. Jones R. Pathology of the skin with clinical correlations, 3rd ed., P.H. McKee, E. Calonje, S.R. Grantner. Elsevier Mosby, Edinburgh (2005), £ 270, ISBN: 0 323 03672 4. J Clin Forensic Med. 2006;13:152–3. [Google Scholar]
  • 23. Dalia S, Sagatys E, Sokol L, Kubal T. Rosai-Dorfman disease: tumor biology, clinical features, pathology, and treatment. Cancer Control. 2014;21(4):322–7. [DOI] [PubMed] [Google Scholar]
  • 24. Wenig BM, Abbondanzo SL, Childers EL, Kapadia SB, Heffner DR. Extranodal sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease) of the head and neck. Hum Pathol. 1993;24(5):483–92. [DOI] [PubMed] [Google Scholar]
  • 25. Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. Arch Pathol. 1969;87(1):63–70. [PubMed] [Google Scholar]
  • 26. Barnes PJ, Foyle A, Haché KA, Langley RG, Burrell S, Juskevicius R. Erdheim-Chester disease of the breast: a case report and review of the literature. Breast J. 2005;11(6):462–7. [DOI] [PubMed] [Google Scholar]
  • 27. Shelley AJ, Kanigsberg N. A unique combination of Rosai-Dorfman disease and mycosis fungoides: a case report. SAGE Open Med Case Rep. 2018;6:2050313x18772195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Al-Khateeb TH. Cutaneous rosai-dorfman disease of the face: a comprehensive literature review and case report. J Oral Maxillofac Surg. 2016;74(3):528–40. [DOI] [PubMed] [Google Scholar]
  • 29. Al-Ghawas MS, Ng T, Chen LYC. Confirmed efficacy of lenalidomide and dexamethasone in unresectable cutaneous facial rosai-dorfman-destombes disease. Mayo Clin Proc Innov Qual Outcomes. 2019;3(1):94–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Choi R, Ring N, McNiff JM, Wilson LD, Martin K, Leventhal J. Treatment of multifocal cutaneous Rosai-Dorfman disease with radiotherapy. JAAD Case Rep. 2022;23:106–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Tirado-Sánchez A. Recalcitrant primary cutaneous Rosai-Dorfman disease. Efficacy of sirolimus and intralesional methylprednisolone. Skin Health Dis. 2023;3(5):e273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. St Claire K, Edriss M, Potts GA. Cutaneous rosai-dorfman disease: a case report. Cureus. 2023;15(5):e39617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Sasaoka Y, Kiyohara E, Nojima S, Kijima N, Ishitsuka Y, Kiyohara E, et al. A case of Rosai-Dorfman disease of the central nerve system associated with cutaneous lesions. J Dermatol. 2024;51(4):e129–30. [DOI] [PubMed] [Google Scholar]
  • 34. Hur K, Hong JY, Kim KH, Jeon J, Lee C, Kwak Y, et al. Facial cutaneous rosai-dorfman disease: dermoscopic findings with successful surgical treatment. Ann Dermatol. 2023;35(Suppl 2):S287–91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Fay CJ, Moslehi D, Iriarte C, Dang TM, Virgen CA, Russell-Goldman E, et al. Treatment-refractory cutaneous Rosai-Dorfman disease responsive to oral methotrexate and topical trametinib. JAAD Case Rep. 2023;39:74–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Balestri R, Magnano M, Pedrolli A, Girardelli CR, Rech G. Treatment of purely cutaneous Rosai Dorfman disease with topical rapamycin. Clin Exp Dermatol. 2023;48(5):545–7. [DOI] [PubMed] [Google Scholar]
  • 37. Roccuzzo G, Avallone G, Cavallo F, Mastorino L, Conti L, Fava P, et al. Synchronous occurrence of primary cutaneous B-cell lymphoma and cutaneous Rosai-Dorfman disease in distinct lesions: a unique association. J Cutan Pathol. 2024;51(1):7–10. [DOI] [PubMed] [Google Scholar]
  • 38. Gitin A, Patel SP, Weatherall A, Vincek V, Motaparthi K. Xanthomatous cutaneous Rosai-Dorfman disease with overlapping features of IgG4-related disease. JAAD Case Rep. 2022;29:134–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Konstantinou MP, Tournier E. Cutaneous Rosai Dorfman disease harboring RET and MAP2K1 mutations, successfully treated with methotrexate. Int J Dermatol. 2022;61(11):1409–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Battista T, Fabbrocini G, Martora L, Martora F. Atypical case of cutaneous Rosai-Dorfman disease. J Cosmet Dermatol. 2023;22(3):1124–6. [DOI] [PubMed] [Google Scholar]
  • 41. Mekheal E, Roman S, Kania B, Mekheal N, Awasthi S, Kumar V, et al. A rare case of benign histiocytic neoplasm of cutaneous rosai-dorfman disease: a case report and literature review. Eur J Case Rep Intern Med. 2022;9(2):003139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Grimaldi M, Perino F, Moretta G, Antonelli F, Paradisi A, Ricci F, et al. Cutaneous Rosai-Dorfman disease after Covid 19 vaccination treated with thalidomide. Dermatol Ther. 2022;35(11):e15864. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Narayanan A, Dharanisankar S, Badhe B, Ramassamy S. Apple-jelly nodules of cutaneous rosai-dorfman disease. Indian Dermatol Online J. 2022;14(3):419–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Maghfour S, Mokni S, Kahla MB, Gammoudi R, Aounallah A, Boussofara L, et al. Cutaneous Rosai-Dorfman disease: A case report. Our Dermatol Online. 2021;12(e):e84. [Google Scholar]
  • 45. Gawdzik A, Ziarkiewicz-Wróblewska B, Chlebicka I, Jankowska-Konsur A, Szepietowski JC, Maj J. Cutaneous rosai-dorfman disease: a treatment challenge. Dermatol Ther. 2021;11(4):1443–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Yuan YX, Xu CX, Zhang RZ. A case of cutaneous rosai-dorfman disease treated by intralesional injections of glucocorticoid. Indian J Dermatol. 2021;66(2):223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Zhang P, Liu F, Cha Y, Zhang X, Cao M. Self-limited primary cutaneous rosai-dorfman disease: a case report and literature review. Clin Cosmet Investig Dermatol. 2021;14:1879–84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Jain M, Pujani M, Sidam D, Wadhwa R, Passi S, Uikey D. Pure cutaneous rosai dorfman disease: an uncommon location for a rare histiocytic proliferative disorder. J Microsc Ultrastruct. 2022;10(2):90–2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Sampaio R, Silva L, Catorze G, Viana I. Cutaneous Rosai-Dorfman disease: a challenging diagnosis. BMJ Case Rep. 2021;14(2):e239244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Kipfer SL, Samycia M, Shiau CJ. Emergence of cutaneous Rosai-Dorfman disease during immunosuppressive treatment of follicular B-cell lymphoma: a case report. SAGE Open Med Case Rep. 2021;9:2050313x211046455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. Montazer F, Farahani S, Shaka Z, Aryanian Z, Goodarzi A. A pure Cutaneous Rosai-Dorfman disease: case report and a review of the literature. Caspian J Intern Med. 2022;13(4):818–26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52. Fayne R, Rengifo SS, Gonzalez I, Solorzano JL, Gonzalez D, Vega F, et al. Primary cutaneous Rosai-Dorfman disease; a case-based review of a diagnostically and therapeutically challenging rare variant. Ann Diagn Pathol. 2020;45:151446. [DOI] [PubMed] [Google Scholar]
  • 53. Bielach-Bazyluk A, Serwin AB, Pilaszewicz-Puza A, Flisiak I. Cutaneous Rosai - dorfman disease in a patient with late syphilis and cervical cancer - case report and a review of literature. BMC Dermatol. 2020;20(1):19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54. Naqvi J, Cassarino DS. Rosai-Dorfman disease-like reaction to tattoo. Am J Dermatopathol. 2020;42(9):680–2. [DOI] [PubMed] [Google Scholar]
  • 55. Wan M, Ding A, Liu H, Ou J, Zhang J. Successful treatment of large cutaneous facial Rosai-Dorfman disease using combination of subtotal resection and ALA-PDT: a case report. Photodiagnosis Photodyn Ther. 2020;31:101879. [DOI] [PubMed] [Google Scholar]
  • 56. Mizuta H, Nakano E, Yamazaki N. Primary cutaneous rosai-dorfman disease of the scalp. Dermatol Pract Concept. 2021;11(1):e2020086. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Ickx F, Tennstedt D, Marot L, Baeck M. Two cases of purely cutaneous Rosai-Dorfman disease. Belgiandermatology. 2019.
  • 58. Karami R, Ghieh F, Baroud J, Abu Sittah G. Rosai-Dorfman disease: cutaneous and parotid involvement. Ann Plast Surg. 2019;82(6):639–41. [DOI] [PubMed] [Google Scholar]
  • 59. Sykes AJ, Lamont D, Tallon B, Mortimer NJ. Rosai-Dorfman disease masquerading as an isolated cutaneous nodule. Australas J Dermatol. 2019;60(4):326–7. [DOI] [PubMed] [Google Scholar]
  • 60. Park AY, Lee HJ, Hong SA, Kim JE. Successful treatment of cutaneous rosai-dorfman disease with pulsed dye laser. Dermatol Surg. 2020;46(2):286–9. [DOI] [PubMed] [Google Scholar]
  • 61. Gan L, Liu WD, Yu WT, Sun JF, Jiang YQ. A case of cutaneous Rosai-Dorfman disease presenting with auricular enlargement as the first manifestation. Indian J Dermatol Venereol Leprol. 2019;85(5):518–22. [DOI] [PubMed] [Google Scholar]
  • 62. Karadag AS, Tekin B, Hurdogan O, Dagdelen D, Dogan O, Buyukbabani N. A case report demonstrating potential utility of topical imiquimod for cutaneous Rosai-Dorfman disease. Dermatol Ther. 2019;32(1):e12759. [DOI] [PubMed] [Google Scholar]
  • 63. Kim YJ, Lee KH, Lee WJ, Won CH, Chang SE, Choi JH, et al. Cutaneous Rosai-Dorfman disease and annular elastolytic giant cell granuloma successively appearing in a case. J Dermatol. 2019;46(12):e470–2. [DOI] [PubMed] [Google Scholar]
  • 64. Song H, Wang T. 5-Aminolevulinic acid photodynamic therapy combined with CO(2) laser therapy for the treatment of cutaneous Rosai-Dorfman disease: a case report. Photodiagnosis Photodyn Ther. 2022;37:102696. [DOI] [PubMed] [Google Scholar]
  • 65. Barona García L, de la Peña Moral JM, Martinez-Escribano J, Ortiz-Reina S. A case of cutaneous rosai-dorfman disease. J Cutan Med Surg. 2018;22(6):633–5. [DOI] [PubMed] [Google Scholar]
  • 66. Subash JJ, Kesty C, Kesty KR, Asgari M, Jorizzo J. Low-dose weekly methotrexate used to treat cutaneous Rosai-Dorfman disease. Clin Exp Dermatol. 2018;43(7):849–51. [DOI] [PubMed] [Google Scholar]
  • 67. Gupta A, Arora P, Batrani M, Sharma PK. Multifocal cutaneous Rosai-Dorfman disease masquerading as lupus vulgaris in a child. An Bras Dermatol. 2018;93(5):766–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68. Yoshimoto N, Iwata Y, Numata S, Saito K, Iwata T, Arima M, et al. Recurrent cutaneous Rosai-Dorfman disease. Eur J Dermatol. 2018;28(4):562–3. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary_material-Suppl.1-s1.docx (14.4KB, docx)

Data Availability Statement

All data generated or analysed during this study are included in this article and its supplementary material files. Further inquiries can be directed to the corresponding author.

Articles from Case Reports in Dermatology are provided here courtesy of Karger Publishers

RESOURCES